Therapeutic Drug Monitoring of Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis: Where Are We Now?
暂无分享,去创建一个
[1] J. Davies,et al. An Update on CFTR Modulators as New Therapies for Cystic Fibrosis , 2022, Pediatric Drugs.
[2] S. N,et al. Dose adjustments of Elexacaftor/Tezacaftor/Ivacaftor in response to mental health side effects in adults with cystic fibrosis. , 2022, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[3] L. Almond,et al. Physiologically‐Based Pharmacokinetic‐Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor‐Tezacaftor‐Ivacaftor With Nirmatrelvir‐Ritonavir for the Treatment of COVID‐19 , 2022, Clinical Pharmacology and Therapeutics.
[4] Suyeon Heo,et al. Mental status changes during elexacaftor/tezacaftor / ivacaftor therapy. , 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[5] D. Teupser,et al. Isotope dilution LC-MS/MS quantification of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators ivacaftor, lumacaftor, tezacaftor, elexacaftor, and their major metabolites in human serum , 2021, Clinical chemistry and laboratory medicine.
[6] E. Kemper,et al. No drug-drug interaction between tezacaftor-ivacaftor and clofazimine: A case report. , 2021, Journal of Cystic Fibrosis.
[7] S. Humphries,et al. Olfactory dysfunction in cystic fibrosis: Impact of CFTR modulator therapy. , 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[8] T. Velkov,et al. Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis , 2021, Frontiers in Pharmacology.
[9] E. Schneider-Futschik,et al. Entry of cystic fibrosis transmembrane conductance potentiator ivacaftor into the developing brain and lung. , 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[10] J. Beekman,et al. Breast development in a 7 year old girl with CF treated with ivacaftor: An indication for personalized dosing? , 2021, Journal of Cystic Fibrosis.
[11] H. Heijerman,et al. CFTR Modulators: Does One Dose Fit All? , 2021, Journal of personalized medicine.
[12] V. Giannetti,et al. Adherence to cystic fibrosis transmembrane conductance regulator (CFTR) modulators: analysis of a national specialty pharmacy database , 2021, Journal of drug assessment.
[13] J. Duckers,et al. Real-World Outcomes of Ivacaftor Treatment in People with Cystic Fibrosis: A Systematic Review , 2021, Journal of clinical medicine.
[14] G. Sawicki,et al. Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. , 2021, The Lancet. Respiratory medicine.
[15] B. Quon,et al. Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review , 2020, Journal of clinical medicine.
[16] A. Neerincx,et al. Quantitative Method for the Analysis of Ivacaftor, Hydroxymethyl Ivacaftor, Ivacaftor Carboxylate, Lumacaftor, and Tezacaftor in Plasma and Sputum Using Liquid Chromatography With Tandem Mass Spectrometry and Its Clinical Applicability , 2020, Therapeutic drug monitoring.
[17] E. Haseltine,et al. Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial , 2020, American journal of respiratory and critical care medicine.
[18] E. Schneider-Futschik,et al. Multiple Reaction Monitoring Mass Spectrometry for the Drug Monitoring of Ivacaftor, Tezacaftor, and Elexacaftor Treatment Response in Cystic Fibrosis: A High-Throughput Method. , 2020, ACS pharmacology & translational science.
[19] E. Haseltine,et al. Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor , 2020, Pulmonary Therapy.
[20] W. Tindell,et al. Trikafta and Psychopathology in Cystic Fibrosis: A Case Report. , 2020, Psychosomatics.
[21] M. Gentzsch,et al. Accumulation and persistence of ivacaftor in airway epithelia with prolonged treatment. , 2020, Journal of Cystic Fibrosis.
[22] S. Rotolo,et al. Testicular pain following initiation of elexacaftor/tezacaftor/ivacaftor in males with cystic fibrosis. , 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[23] E. O’Grady,et al. Evidence of Small Airways Disease and the Immediate Effects of Lumacaftor/Ivacaftor in Children with Cystic Fibrosis. , 2020, Irish medical journal.
[24] E. Nash,et al. Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators - an international survey. , 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[25] Nicolas Widmer,et al. The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib , 2020, Frontiers in Pharmacology.
[26] E. Acosta,et al. Variable cellular ivacaftor concentrations in people with cystic fibrosis on modulator therapy. , 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[27] B. Ramsey,et al. The Changing Face of Cystic Fibrosis , 2020 .
[28] M. Lopes-Pacheco. CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine , 2020, Frontiers in Pharmacology.
[29] S. Mulrennan,et al. To be or not to be on CFTR modulators during pregnancy: Risks to be considered. , 2019, Journal of Cystic Fibrosis.
[30] C. Teneback,et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial , 2019, The Lancet.
[31] I. Sermet-Gaudelus,et al. Predictive factors for lumacaftor/ivacaftor clinical response. , 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[32] C. Taube,et al. Use of ivacaftor in late diagnosed cystic fibrosis monozygotic twins heterozygous for F508del and R117H-7T – a case report , 2019, BMC Pulmonary Medicine.
[33] V. Garg,et al. Pharmacokinetic and Drug–Drug Interaction Profiles of the Combination of Tezacaftor/Ivacaftor , 2019, Clinical and translational science.
[34] J. Alffenaar,et al. Role of Therapeutic Drug Monitoring in Treatment Optimization in Tuberculosis and Diabetes Mellitus Comorbidity , 2018, Antimicrobial Agents and Chemotherapy.
[35] E. Stringer,et al. Measured fetal and neonatal exposure to Lumacaftor and Ivacaftor during pregnancy and while breastfeeding. , 2018, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[36] M. Rosenfeld,et al. Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. , 2018, The Lancet. Respiratory medicine.
[37] R. Young,et al. Lipophilicity of the Cystic Fibrosis Drug, Ivacaftor (VX-770), and Its Destabilizing Effect on the Major CF-causing Mutation: F508del , 2018, Molecular Pharmacology.
[38] C. Benden,et al. First experience in Switzerland in Phe508del homozygous cystic fibrosis patients with end-stage pulmonary disease enrolled in a lumacaftor-ivacaftor therapy trial - preliminary results. , 2018, Swiss medical weekly.
[39] J. Pilewski,et al. Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del‐CFTR or F508del/G551D‐CFTR , 2018, American journal of respiratory and critical care medicine.
[40] S. Donaldson,et al. Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation. , 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[41] G. Lukács,et al. Mutation-specific downregulation of CFTR2 variants by gating potentiators , 2017, Human molecular genetics.
[42] M. Barry,et al. The pharmacokinetic interaction between ivacaftor and ritonavir in healthy volunteers , 2017, British journal of clinical pharmacology.
[43] Karl Aberer,et al. TUCUXI: An Intelligent System for Personalized Medicine from Individualization of Treatments to Research Databases and Back , 2017, BCB.
[44] S. Dhillon,et al. Drug-induced dyspnea versus cystic fibrosis exacerbation: a diagnostic dilemma , 2017, International medical case reports journal.
[45] R. Altman,et al. PharmGKB summary: ivacaftor pathway, pharmacokinetics/pharmacodynamics , 2017, Pharmacogenetics and genomics.
[46] G. Tucker. Personalized Drug Dosage – Closing the Loop , 2016, Pharmaceutical Research.
[47] E. Deeks. Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis , 2016, Drugs.
[48] J. Clancy,et al. Electronic monitoring reveals highly variable adherence patterns in patients prescribed ivacaftor. , 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[49] Xiaohong Huang,et al. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. , 2015, The New England journal of medicine.
[50] V. Carbone,et al. Drug–drug plasma protein binding interactions of ivacaftor , 2015, Journal of molecular recognition : JMR.
[51] N. Dokholyan,et al. Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis , 2014, Science Translational Medicine.
[52] R. Trittler,et al. PKP-017 Monitoring of ivacaftor serum levels , 2014 .
[53] M. Baumgartner,et al. One-year evaluation of a neonatal screening program for cystic fibrosis in Switzerland. , 2013, Deutsches Arzteblatt international.
[54] T. Hwang,et al. Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle , 2013, Proceedings of the National Academy of Sciences.
[55] T. Buclin,et al. Safe and Effective Variability—A Criterion for Dose Individualization , 2012, Therapeutic drug monitoring.
[56] A. Park,et al. CENTER FOR DRUG EVALUATION AND RESEARCH , 2009 .
[57] B. Kirby,et al. Effects of Pregnancy on CYP3A and P‐glycoprotein Activities as Measured by Disposition of Midazolam and Digoxin: A University of Washington Specialized Center of Research Study , 2008, Clinical pharmacology and therapeutics.
[58] A. Sabers,et al. Individual changes in lamotrigine plasma concentrations during pregnancy , 2005, Epilepsy Research.
[59] A. S. Gross,et al. Best practice in therapeutic drug monitoring. , 2001, British journal of clinical pharmacology.
[60] M. Ingelman-Sundberg,et al. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. , 1995, The Journal of pharmacology and experimental therapeutics.